Eli Lilly's $1.2B all-cash acquisition of Ventyx closed March 2026, returning capital to shareholders at a 62% premium — no remaining public investment thesis exists

Ventyx Biosciences was a clinical-stage company developing targeted drugs for inflammatory bowel disease that was acquired by Eli Lilly in March 2026 and no longer exists as a public company.

Ventyx Biosciences was acquired by Eli Lilly in a completed $1.2 billion all-cash transaction at $14.00 per share, closing March 4, 2026. No publicly traded equity or active pipeline programs remain — the company no longer exists as an investable entity. The acquisition resolves all prior thesis questions; there is no residual risk or upside for public shareholders.